CELZ Stock Overview A commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Creative Medical Technology Holdings, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Creative Medical Technology Holdings Historical stock prices Current Share Price US$2.17 52 Week High US$10.28 52 Week Low US$1.96 Beta 4.91 1 Month Change -14.73% 3 Month Change -29.78% 1 Year Change -54.12% 3 Year Change -89.62% 5 Year Change -99.04% Change since IPO -100.00%
Recent News & Updates
Creative Medical Technology Holdings, Inc. Advances FDA Cleared ADAPT Clinical Trial with Positive Independent Review, Validating the Safety and Potential of CELZ-201 for Chronic Lower Back Pain Treatment Nov 14
New minor risk - Shareholder dilution Nov 06
Creative Medical Technology Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $1.85 million. Oct 24 Creative Medical Technology Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $1.85 million. Oct 23
New minor risk - Share price stability Sep 10
Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin Jun 24 See more updates
Creative Medical Technology Holdings, Inc. Advances FDA Cleared ADAPT Clinical Trial with Positive Independent Review, Validating the Safety and Potential of CELZ-201 for Chronic Lower Back Pain Treatment Nov 14
New minor risk - Shareholder dilution Nov 06
Creative Medical Technology Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $1.85 million. Oct 24 Creative Medical Technology Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $1.85 million. Oct 23
New minor risk - Share price stability Sep 10
Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin Jun 24
Creative Medical Technology Holdings, Inc., Annual General Meeting, Jul 19, 2024 May 21
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Mar 24
New minor risk - Share price stability Mar 08
Creative Medical Technology Holdings Inc. Announces FDA Authorization for Type 1 Diabetes Prevention Therapy Under Expanded Access Mar 07
Creative Medical Technology Holdings, Inc. Receives Clearance from the FDA to Conduct a Phase 1/2 Clinical Trial Using Their Innovative StemSpine Treatment Known as AlloStem Dec 20
New major risk - Financial position Nov 17
Creative Medical Technology Holdings, Inc., Annual General Meeting, Dec 20, 2023 Nov 04
Creative Medical Technology Holdings, Inc. Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Stemspine(R) Using Allostem(Tm) (Celz-201-Ddt) Novel Cell Therapy to Treat Chronic Lower Back Pain Oct 11
Creative Medical Technology Holdings Receives FDA Clearance to Initiate A Phase 1/2 Clinical Trial of Stemspine® Using Allostem™ (Celz-201-Ddt) for the Treatment of Chronic Lower Back Pain Sep 20
Creative Medical Technology Holdings Regains Compliance with Nasdaq Listing Requirements Jun 30
Creative Medical Technology Holdings, Inc. (NasdaqCM:CELZ) announces an Equity Buyback for $2 million worth of its shares. Jun 13
Creative Medical Technology Holdings Announces Successful Completion of the First Phase of Its Program with Greenstone Biosciences, Inc. to Develop Next Generation iPSC Pipeline for ImmCelz(R) Immunotherapy Platform Jun 01
Creative Medical Technology Holdings, Inc. Announces Next Milestone Achievements in ImmCelz Platform Development May 23
Creative Medical Technology Holdings Announces Positive Top-Line Study Results for Chronic Lower Back Pain Utilizing its StemSpine® Procedure Using AlloStem™ Allogenic Cell Line May 19
Creative Medical Technology Holdings, Inc. Announces Positive Three-Year Follow-Up Data for the Company's Stemspine Pilot Study Feb 15
Creative Medical Technology Holdings, Inc. Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Novel Cell Therapy for the Treatment of Type 1 Diabetes Feb 09
High number of new and inexperienced directors Nov 16
Creative Medical Technology Holdings, Inc. Announces Fda Clearance of Investigational New Drug (Ind) Application for Allostem(Tm), A Novel Cell Therapy for the Treatment of Type 1 Diabetes Nov 04
Creative Medical Technology Holdings, Inc., Annual General Meeting, Dec 19, 2022 Oct 27
Creative Medical Technology Holdings, Inc. Develops AlloStem Clinical Cell Line Oct 21
Creative Medical Technology Announces Positive Top-Line Results for OvaStem® Pilot Study Jul 29
Creative Medical Technology Holdings Receives Non-Compliance Notice from Nasdaq Jul 16 Creative Medical Technology Holdings, Inc. announced that it has received $17.000001 million in funding May 06
High number of new and inexperienced directors Apr 27
Creative Medical Technology Holdings, Inc. Announces Progress in Developing a Reproducible Clinical Grade of the Company's ImmCelz® Product Apr 21
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Apr 01
Creative Medical Technology Appoints Sahil Nock as Chief Commercial Officer Mar 04
Creative Medical Technology Appoints Sahil Nock as Chief Commercial Officer Mar 03
High number of new and inexperienced directors Jan 02
Creative Medical Technology Holdings Deleted from Other OTC Dec 05
Less than half of directors are independent Dec 04
Creative Medical Technology Holdings, Inc. announced that it has received $3.78775 million in funding Aug 13
Creative Medical Technology Holdings, Inc. announced that it expects to receive $3.788 million in funding Aug 10
Creative Medical Technology Holdings Identifies Synergy Between Immcelz® Regenerative Immunotherapy and Myeloid Suppressor Cells in Treatment of Type 1 Diabetes Jun 10
Creative Medical Technology Holdings Expands Neurological Application of ImmCelz® into Parkinson's Disease May 25
FDA Responds to Creative Medical Technology Holdings, Inc. Regarding its ImmCelz® IND for Stroke Treatment May 15
Creative Medical Technology Holdings, Inc. Announces Fda Acknowledgment of Ind Application for Immcelz® to Treat Stroke Mar 17
Creative Medical Technology Holdings Publishes Efficacy in Pain Reduction and Mobility in Patients with Disc Degenerative Disc Using Stemspine® Personalized Adult Stem Cell Therapy Mar 05
Creative Medical Technology Holdings Provides Update on ImmCelz® FDA Application Mar 04
Creative Medical Technology Holdings Files Patent on Prevention of Organ Transplant Rejection Using ImmCelz® Feb 18
Creative Medical Technology Holdings Identifies Cellular Mechanism of Patented Ovastem® Female Infertility/Ovarian Failure Treatment Feb 11
Creative Medical Technology Holdings, Inc. Announces the Recruitment of Dr. Caigan Du to the Scientific Advisory Board Feb 09
Creative Medical Technology Holdings Identifies and Files Patent on Novel Mechanism of Immcelz® Therapeutic Activity Feb 02 Creative Medical Technology Holdings Inc. Recruits Dr. Boris Reznik to the Scientific Advisory Board
Creative Medical Technology Holdings Inc. Files Investigational New Drug Application with FDA for Treatment of Stroke using ImmCelz® Regenerative Immunotherapy Jan 13
Creative Medical Technology Holdings Announces Patent Filing Based on Preclinical Data in Model of Heart Attack Using ImmCelz Regenerative Immunotherapy Jan 01
Creative Medical Technology Holdings Announces Successful Application of ImmCelz® Immunotherapy for Treatment of Stroke Dec 18
Creative Medical Technology Holdings Files Patent on Induction of Infectious Tolerance by Ex Vivo Reprogrammed Immune Cells Utilizing ImmCelz® Cellular Immunotherapy Dec 13
Creative Medical Technology Holdings Reports Positive Preclinical Data on ImmCelz® Immunotherapy Product in Rheumatoid Arthritis Model Sep 30 Shareholder Returns CELZ US Biotechs US Market 7D -7.3% -3.8% -2.7% 1Y -54.1% -2.6% 23.4%
See full shareholder returns
Return vs Industry: CELZ underperformed the US Biotechs industry which returned -2.6% over the past year.
Return vs Market: CELZ underperformed the US Market which returned 23.4% over the past year.
Price Volatility Is CELZ's price volatile compared to industry and market? CELZ volatility CELZ Average Weekly Movement 16.1% Biotechs Industry Average Movement 10.7% Market Average Movement 6.3% 10% most volatile stocks in US Market 16.9% 10% least volatile stocks in US Market 3.2%
Stable Share Price: CELZ's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CELZ's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure.
Show more Creative Medical Technology Holdings, Inc. Fundamentals Summary How do Creative Medical Technology Holdings's earnings and revenue compare to its market cap? CELZ fundamental statistics Market cap US$3.62m Earnings (TTM ) -US$5.32m Revenue (TTM ) US$11.00k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) CELZ income statement (TTM ) Revenue US$11.00k Cost of Revenue US$4.40k Gross Profit US$6.60k Other Expenses US$5.32m Earnings -US$5.32m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -3.04 Gross Margin 60.00% Net Profit Margin -48,345.28% Debt/Equity Ratio 0.2%
How did CELZ perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 23:16 End of Day Share Price 2024/12/23 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Creative Medical Technology Holdings, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Jonathan Aschoff Roth MKM
Show 0 more analysts 
